FDA warns Young Living & doTerra for false product claims
The FDA recently sent letters to both Young Living and doTerra, warning them that they had observed instances of their products being promoted for conditions that cause them to be drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. ยง 321(g)(1)(B)], because they are intended for use in [Continue reading…]